Calcipotriene and betamethasone dipropionate cream demonstrates superior efficacy in moderate plaque psoriasis compared to topical suspension: a subgroup analysis of a phase 3 trial

Linda Stein Gold,April Armstrong,Morten Præstegaard,John Selmer

doi:10.25251/skin.6.supp.10

Abstract

N/A

Highlights

The objective of this subgroup analysis is to present data from a Phase 3 trial on the efficacy and convenience of CAL/BDP cream in patients with moderate plaque psoriasis compared to CAL/BDP topical suspension (TS)
The Physician Global Assessment (PGA) treatment success in patients with moderate psoriasis was significantly greater for CAL/BDP cream (45.3%) than for CAL/BDP TS (27.5%) at Week 8 (p
At week 8, this increased to 88.4% of patients in the CAL/BDP cream group compared to 72.6% in the CAL/BDP TS group (p

Summary

INTRODUCTION

Calcipotriene and betamethasone dipropionate (50 microgram/g CAL and 0.5 mg/g BDP) cream (CAL/BDP cream) is based on PADTM Technology enabling development of an easy to apply, aqueous cream of CAL and BDP, despite their known pH-related instability when combined in the presence of water. The objective of this subgroup analysis is to present data from a Phase 3 trial on the efficacy and convenience of CAL/BDP cream in patients with moderate plaque psoriasis compared to CAL/BDP topical suspension (TS)

METHODS

RESULTS

Findings

CONCLUSIONS